Unknown

Dataset Information

0

In silico prediction and structure-based multitargeted molecular docking analysis of selected bioactive compounds against mucormycosis


ABSTRACT:

Background

During the second wave of the COVID-19 pandemic, an unusual increase in cases of mucormycosis was observed in India, owing to immunological dysregulation caused by the SARS-CoV-2 and the use of broad-spectrum antibiotics, particularly in patients with poorly controlled diabetes with ketoacidosis to have contributed to the rise, and it has been declared an epidemic in several states of India. Because of the black colouring of dead and dying tissue caused by the fungus, it was dubbed "black fungus" by several Indian media outlets. In this study, attempts were taken to unmask novel therapeutic options to treat mucormycosis disease. Rhizopus species is the primary fungi responsible for 70% of mucormycosis cases.

Results

We chose three important proteins from the Rhizopus delemar such as CotH3, Lanosterol 14 alpha-demethylase and Mucoricin which plays a crucial role in the virulence of Mucorales. Initially, we explored the physiochemical, structural and functional insights of proteins and later using AutoDock Vina, we applied computational protein–ligand binding modelling to perform a virtual screening around 300 selected compounds against these three proteins, including FDA-approved drugs, FDA-unapproved drugs, investigational-only drugs and natural bioactive compounds. ADME parameters, toxicity risk and biological activity of those compounds were approximated via in silico methods. Our computational studies identified six ligands as potential inhibitors against Rhizopus delemar, including 12,28-Oxamanzamine A, vialinin B and deoxytopsentin for CotH3; pramiconazole and saperconazole for Lanosterol 14 alpha-demethylase; and Hesperidin for Mucoricin. Interestingly, 12,28-Oxamanzamine A showed a maximum binding affinity with all three proteins (CotH3: − 10.2 kcal/mol Lanosterol 14 alpha-demethylase: − 10.9 kcal/mol Mucoricin: − 8.6 kcal/mol).

Conclusions

In summary, our investigation identified 12,28-Oxamanzamine A, vialinin B, deoxytopsentin, pramiconazole, saperconazole and hesperidin as potent bioactive compounds for treating mucormycosis that may be considered for further optimisation techniques and in vitro and in vivo studies.

Supplementary Information

The online version contains supplementary material available at 10.1186/s42269-022-00704-4.

SUBMITTER: Madanagopal P 

PROVIDER: S-EPMC8802264 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6823401 | biostudies-literature
| S-EPMC9653785 | biostudies-literature
| S-EPMC7652978 | biostudies-literature
| S-EPMC6225388 | biostudies-other
| S-EPMC8950821 | biostudies-literature
| S-EPMC8037217 | biostudies-literature
| S-EPMC9734692 | biostudies-literature
| S-EPMC8088405 | biostudies-literature
| S-EPMC6995630 | biostudies-literature